The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) has approved a dividend of EUR 0.22 per share for the 2025 fiscal year, marking a significant increase from the previous year's EUR 0.17 per share. The resolution, proposed by the Executive Board and Supervisory Board, was passed with a large majority, reflecting shareholder confidence in the company's financial health and strategic direction.
Held as an in-person event near the company's headquarters in Berlin, the meeting saw 55.37% of the share capital represented. Shareholders also endorsed the actions of the Executive Board and Supervisory Board for the 2025 fiscal year, approving all agenda items. The detailed voting results and the CEO's presentation are available on the Eckert & Ziegler website.
This dividend increase underscores Eckert & Ziegler's robust financial performance and its commitment to delivering value to shareholders. As a leading specialist in isotope-related components for nuclear medicine and radiation therapy, the company continues to benefit from growing demand in the radiopharmaceutical industry. With over 1,000 employees, Eckert & Ziegler offers a comprehensive range of services and products, from early development to contract manufacturing and distribution.
The company's shares are listed in the TecDAX index of Deutsche Börse, and this dividend hike is likely to attract further investor interest. The decision aligns with the company's long-term strategy of balancing reinvestment in growth with shareholder returns. Eckert & Ziegler's focus on saving lives through its contributions to nuclear medicine remains central to its mission, and the increased dividend signals confidence in its ongoing projects and market position.
For more information, investors can refer to the official documents posted on the company's investor relations page. The strong approval rates at the meeting indicate solid support for the management's vision and the company's trajectory in the competitive radiopharmaceutical sector.
